Factor X Deficiency

Global biopharma company encourages education and awareness around a rare bleeding disorder. FORT LEE, N.J., Oct. 10, 2023 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, is proud to recognize the fourth Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2023. This day helps bring awareness to a rare bleeding disorder, the patients it impacts, their challenges, and the treatments that can help. Continue Reading Factor X Day was launched on 10/1020 by U.K.-based Bio Products Laboratory (BPL). In 2022, Kedrion joined forces with BPL. The new Kedrion is a global player in plasma derivatives and rare disease medicines, employing more than 5,000 people worldwide. Kedrion Biopharma is proud to recognize the fourth Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2023 Tweet this About one in a million people have hereditary factor X deficiency, which causes unusual or excessive bleeding or bruising, heavy menstrual bleeding in women, painful or swollen joints, nose bleeds, and bleeding gums. Although the disorder is ultra-rare, some patients with severe factor X deficiency could experience life-threatening complications like bleeding in the brain or stomach. Because symptoms vary, patients may suffer for years before being diagnosed. A simple blood test can determine whether someone has the disorder and can be treated with plasma-based treatments. John, one of the oldest known patients with severe hereditary factor X deficiency at age 51, says it best. "Since being diagnosed when I was a year old, I have had to go to the hospital about 150 times for transfusions of fresh frozen plasma to treat bleeds that were not controlled by themselves. As someone living with hereditary factor X deficiency, I want everyone to be more aware of this rare disease and why it is so important to get care and treatment." "We are excited for the first Hereditary Factor X Deficiency Awareness Day since Kedrion joined forces with Bio Products Laboratory in 2022," said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. "With over 60 years of combined expertise across the United Kingdom, United States, and Italy, we are delighted to continue raising awareness for hereditary factor X deficiency and providing therapies to support patients, their caregivers, and families on the journey from diagnosis to treatment." Kedrion is committed to providing therapies for rare diseases to improve patients' health as they manage bleeding disorders like hereditary factor X deficiency. To learn more about hereditary factor X deficiency, visit . About Kedrion Kedrion Biopharma is a global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating and preventing serious diseases, disorders, and conditions like plasminogen deficiency, hereditary factor X deficiency, and hemophilia. Its portfolio of 37 life-saving products is distributed in over 100 countries. kedrion.com Contact Information: Sandy Sklareski Communications Manager [email protected] 551-255-6557 SOURCE Kedrion Biopharma

DURHAM, N.C., Oct. 10, 2022 /PRNewswire/ -- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, is proud to partner with the National Hemophilia Foundation in recognizing the third annual Hereditary Factor X (10) Deficiency Awareness Day, October 10, 2022. This day aims to bring a very rare bleeding disorder to the forefront of people's minds, including the patients it impacts, the challenges they face, and the treatments that might help. About one in a million people have Hereditary Factor X Deficiency, which may cause unusual or excessive bleeding or bruising, heavy menstrual bleeding in women, painful or swollen joints, nose bleeds, and bleeding gums. Serious bleeding in the brain or stomach is also possible. Because the symptoms are so varied, patients may suffer for years before being diagnosed. Thankfully, a simple blood test can be done to determine whether someone has the disorder, and it can be treated with plasma-based treatments. Carly, a mother of two children diagnosed with Hereditary Factor X Deficiency, says it best. "I love to share the story of Factor X Deficiency and what my family has gone through because we have so many experiences – good and bad - that I would like to share so that people don't necessarily have to go through what my family went through." "After seeing the community engagement of Hereditary Factor X Awareness Day over the past two years, we more clearly understand the importance of raising awareness around Hereditary Factor X Deficiency for those living with the disorder and those yet to be diagnosed," notes Bob Rossilli, US President and Chief Commercial Officer, Global Business for BPL. "We hope this day as well as ongoing efforts throughout the year help generate greater awareness of the signs and symptoms of Hereditary Factor X Deficiency. Our goal is to reach as many people and healthcare providers as possible because the "one in a million" could be their patient or loved one." "Factor X Day is such an important day for our community – it reminds those with this rare condition that they are never alone, and that there is always a community of support waiting for them," said Kate Nammacher, the Vice President of Education at the National Hemophilia Foundation. "We at NHF are thankful for the partnership with BPL in raising awareness and celebrating the voices of those living with Factor X Deficiency today, and every day." The first Hereditary Factor X Deficiency Awareness Day was on 10/10/20. To learn more about Hereditary Factor X Deficiency, visit . About Bio Products Laboratory (BPL) Recognizing the power of plasma and with over 60 years heritage in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients, and customers globally. BPL is headquartered in Elstree, United Kingdom, where its manufacturing operations are located. BPL USA Inc. offices are in Durham, North Carolina. BPL is dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well as for critical care. BPL invests in the latest R&D, technology, and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit or SOURCE Bio Products Laboratory USA

Data presented at the 2022 Thrombosis & Hemostasis Summit of North America DURHAM, N.C., Aug. 16, 2022 /PRNewswire/ -- Bio Products Laboratory USA (BPL), a leading manufacturer of plasma-derived protein therapies, today presented initial data from the Hereditary Factor X Deficiency (HFXD) in America Survey at the Thrombosis and Hemostasis Summit of North America (THSNA) in Chicago, IL. The HFXD in America Survey is the first survey of its kind to directly assess the long and difficult journey from diagnosis to treatment for patients and caregivers suffering from Hereditary Factor X Deficiency, as well as seeks to better understand the significant disease burden, quality of life issues and other factors that impact overall care and well-being. HFXD is a rare bleeding disorder affecting 1 in 1 million individuals and this innovative survey provides valuable insight into this rare disease. According to the survey's lead expert, Brian Branchford, MD, Associate Medical Director of the Versiti Medical Sciences Institute, Associate Investigator at the Versiti Blood Research Institute, and Associate Professor of Pediatrics, Hematology/Oncology at the Medical College of Wisconsin, the survey fills a critical gap in knowledge and understanding about patients and caregivers impacted by this rare orphan disease. "The impact of rare coagulation disorders on patients and their caregivers is often underrepresented. In addition to clinical data, it is critically important that we better understand how these disorders impact patients' health and well-being. The HFXD in America Survey is an important step along that path for clinicians who provide care for patients with HFXD." The survey included a national, cross-sectional sample of patients with Hereditary Factor X Deficiency and their associated caregivers. Participants were recruited through Hemophilia Treatment Centers (HTCs), rare bleeding disorder patient advocacy groups, and social media. Overall, 30 patients and 38 caregivers completed the survey, which represents robust input from approximately 10% of the estimated patients with HFXD in the United States. While the majority of patients in the survey reported receiving treatment after their diagnosis with HFXD, their current treatments varied significantly. Despite expert consensus recommendations advising clinicians to use single-factor replacement therapy for hereditary bleeding disorders1,2, only about half of patients in this survey reported treatment with single factor replacement therapy either as monotherapy or in combination with other treatments. Furthermore, approximately 1 in 4 patients in the survey reported receiving fresh frozen plasma (FFP). Perhaps of concern, many patients reported still having bleeding episodes in the four weeks prior to taking the survey, suggesting a need to better optimize their treatment plan. Overall quality of life (QoL) and well-being were lower for patients with HFXD versus the general population, and caregivers also reported the negative impact of HFXD on QoL, although caregivers did also report high positive aspects of caregiving, including self-worth and inner strength. "We have definitely come a long way in treating patients with HFXD," said Eric Wolford, PharmD, Vice President of Global Medical for BPL, "but the survey demonstrates significant gaps and opportunities to improve care and treatment." BPL looks forward to continuing the analysis of this important data and publishing further insights that may contribute to helping improve the overall care and quality of life for patients with HFXD and their caregivers. Additional data from the HFXD Survey in America will be presented at the National Hemophilia Foundation (NHF) 74th Annual Bleeding Disorders Conference in Houston, Texas later this month. 1. National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC). MASAC Document 272. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. National Hemophilia Foundation. Accessed August 12, 2022. 2. Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, Schramm W, Mannucci PM. Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia. 2014 May;20(3):322-5. doi: 10.1111/hae.12440. PMID: 24731129. About Bio Products Laboratory (BPL) Recognizing the importance of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients, and customers globally. Headquartered in the United Kingdom, with US offices in Durham, NC, and plasma collection centers across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit or . BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors in around 28 centers across the U.S. BPL Plasma employs over 900 staff to support the needs of donors and to ensure high-quality plasma collection in all their centers. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follows industry guidelines. BPL Plasma operates plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services, and administrative activities. BPL's plasma-derived medicines are commercially available in the U.K., USA, and 30 plus other countries around the world through our network of local affiliates and distribution partners. SOURCE Bio Products Laboratory USA